Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials
They are typically taken at higher doses for weight loss than for diabetes
Over the past decades, several randomized clinical trials (RCTs) have shown that GLP-1 RAs improve cardiovascular outcomes in patients with type 2 DM (T2DM) who have established CVDs or are at risk, as well as in individuals with CKD [16,17,18,19]
Depending on your tax bracket, this effectively gives you a 22-32% discount on retatrutide costs
This combination explains why clinical trials showed superior weight loss compared to single or dual-agonist medications
However, your doctor will have to give the go-ahead for this, as compounds can have more side effects than GLP-agonists